Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
mTOR–neuropeptide Y signaling sensitizes nociceptors to drive neuropathic pain
Lunhao Chen, Yaling Hu, Siyuan Wang, Kelei Cao, Weihao Mai, Weilin Sha, Huan Ma, Ling-Hui Zeng, Zhen-Zhong Xu, Yong-Jing Gao, Shumin Duan, Yue Wang, Zhihua Gao
Lunhao Chen, Yaling Hu, Siyuan Wang, Kelei Cao, Weihao Mai, Weilin Sha, Huan Ma, Ling-Hui Zeng, Zhen-Zhong Xu, Yong-Jing Gao, Shumin Duan, Yue Wang, Zhihua Gao
View: Text | PDF
Research Article Neuroscience

mTOR–neuropeptide Y signaling sensitizes nociceptors to drive neuropathic pain

  • Text
  • PDF
Abstract

Neuropathic pain is a refractory condition that involves de novo protein synthesis in the nociceptive pathway. The mTOR is a master regulator of protein translation; however, mechanisms underlying its role in neuropathic pain remain elusive. Using the spared nerve injury–induced neuropathic pain model, we found that mTOR was preferentially activated in large-diameter dorsal root ganglion (DRG) neurons and spinal microglia. However, selective ablation of mTOR in DRG neurons, rather than microglia, alleviated acute neuropathic pain in mice. We show that injury-induced mTOR activation promoted the transcriptional induction of neuropeptide Y (Npy), likely via signal transducer and activator of transcription 3 phosphorylation. NPY further acted primarily on Y2 receptors (Y2R) to enhance neuronal excitability. Peripheral replenishment of NPY reversed pain alleviation upon mTOR removal, whereas Y2R antagonists prevented pain restoration. Our findings reveal an unexpected link between mTOR and NPY/Y2R in promoting nociceptor sensitization and neuropathic pain.

Authors

Lunhao Chen, Yaling Hu, Siyuan Wang, Kelei Cao, Weihao Mai, Weilin Sha, Huan Ma, Ling-Hui Zeng, Zhen-Zhong Xu, Yong-Jing Gao, Shumin Duan, Yue Wang, Zhihua Gao

×

Figure 7

NPY enhances nociceptor excitability through Y2R.

Options: View larger image (or click on image) Download as PowerPoint
NPY enhances nociceptor excitability through Y2R.
(A) Representative AP ...
(A) Representative AP traces elicited by intracellular injection of 110 pA depolarizing currents on dissociated DRG neurons from resting membrane potentials (RMP) in Mtorfl/fl mice and Mtor-cKOAdv mice with or without SNI at day 7 after surgery. NPY (300 nM), BIBO3304 (1 μM), and BIIE0246 (1 μM) are replenished in medium as indicated. (B) The responses of Mtorfl/fl and Mtor-cKOAdv DRG neurons across a series of 500 ms depolarizing current pulses in 10 pA increment from 0 pA to 130 pA, in the presence or absence of NPY, BIBO3304, or BIIE0246 (n = 10–13 neurons from 3 mice per group). (C) Quantification of APs evoked by input current at 110 pA (n = 10–13 neurons from 3 mice per group). (D) Averaged values of rheobase currents in DRG neurons among groups measured in current-clamp (I-clamp) (n = 10–13 from 3 mice neurons per group). (E and F) Quantification of membrane capacitance (E) and RMP (F) among groups (n = 10–13 neurons from 3 mice per group). BIBO3304, Y1R antagonist; BIIE0246, Y2R antagonist. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA followed by Bonferroni’s post hoc tests among groups. AP, action potential; RMP, resting membrane potentials.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts